The SNMMI is already over, time flew by fast ! We were so happy to meet you there.
The show went great this year, we ended up with a lot of promising projects. The FDA approval of Trasis FDOPA's process was among other the icing of the cake.
If you missed us but would like to get updated on Trasis' products, feel free to contact us.
Our team will be delighted to meet you at the ISRS in Beijing this year.
You can make an appointment or meet us on our booth.
The EANM already seems so far away... We really miss the intensity of having a booth full of people every single day! This edition might be over on the paper but it is still running through our heads. We then couldn't resist to share some of the best moments with you.
Düsseldorf, 15 October 2018 : Trasis' Community Meeting.
Düsseldorf, 15 October 2018.
Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.
AllinOne family versatility proven
Three months after its approval by the American FDA, Trasis’ FDG Dual method obtains its Market Authorization for Belgium and the Netherlands.
Trasis and Radboud Translational Medicine (RTM) worked together and finalized the Marketing Authorization National Phase for FDG production on AllinOne synthesizers.
Ans, 11 October 2018 – We are pleased to announce that we have entered into an agreement with RQS. Ruffani Quality Solutions will be our agent and provide service support for Germany and Austria.
With decades of experience and jointly to Trasis, RQS are committed to listening to our customers in order to provide the most effective solution. Located in Heideneau, RQS is also a valued partner and able to offer technical support in Germany and Austria.
